Geeske F. Grit

Geeske F. Grit

Auto-generated profile, based on publicly available information

Geeske F. Grit

Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Lung Cancer
Verified
Journal Article
Open access
GGGeeske F Grit
Geeske F Grit
EGEsmée van Geffen
Esmée van Geffen
RMRuben Malmberg
Ruben Malmberg
RLRoelof van Leeuwen
Roelof van Leeuwen
SBStefan Böhringer
Stefan Böhringer
DHDoranne Hilarius
Doranne Hilarius
High and increasing expenses on pembrolizumab ask for more cost-effective and sustainable treatment strategies to improve affordability of healthcare. Therefore, a part of the Dutch hospitals implemented an alternative, partially lower, weight-based dosing protocol for pembrolizumab. This provided the unique opportunity to compare the overall survival (OS) of the alternative pembrolizumab dosing protocol to standard dosing using a nationwide registry in non-small cell lung cancer (NSCLC) patients. This is a retrospective cohort study with a non-inferiority primary objective. Forty hospitals in the Dutch Medication Audit and Dutch Lung Cancer Audit treated 1966 patients with NSCLC with first line pembrolizumab (mono- or combination therapy) between Jan 1st 2021, and Mar 31st, 2023. Alternative weight-based pembrolizumab dosing (100/150/200 mg Q3W or 200/300/400 mg Q6W) was administered to 604 patients, and 1362 patients received standard pembrolizumab dosing (200 mg Q3W or 400 mg Q6W). A Cox proportional hazard model with selected covariates was used to compare the OS between alternative and standard dosing protocols. The non-inferiority margin was set at a hazard ratio (HR) of 1.2 for OS. Non-inferiority is established by showing that the upper limit of the 95 % confidence interval (CI) of the HR of OS is smaller or equal to 1.2. Distribution of age (66.7 years +/-9.4), sex (45 % female) and treatment combinations were similar for both groups, comorbidity score was higher in the standard group. Median daily dose in the alternative dosing group was 22 % lower compared to the standard dosing group, 7.14 mg/day (interquartile range (IQR):5.48-8.04 mg/day) vs. 9.15 mg/day (IQR:8.33-9.52 mg/day), respectively. Alternative dosing was non-inferior to standard dosing regarding overall survival (adjusted HR 0.83, 95 %CI:0.69-1.003). This large, retrospective real-world analysis supports the hypothesis that the alternative, partially lower pembrolizumab dosing protocol in NSCLC maintains treatment effectiveness while reducing treatment costs.

27 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GGGeeske F. Grit
Geeske F. Grit
AMAnne-Grete Märtson
Anne-Grete Märtson
MKMarjolein Knoester
Marjolein Knoester
MTMarlous L. Toren-Wielema
Marlous L. Toren-Wielema
Daniel Johannes TouwDaniel Johannes Touw
Daniel Johannes Touw
Background: Acyclovir and valacyclovir are used for the treatment and prophylaxis of infections with herpes simplex virus (HSV) and varicella zoster virus (VZV). The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir. Methods: Patients were retrospectively selected, based on therapeutic drug monitoring for acyclovir, to create a population pharmacokinetic (PK) model in Pmetrics. This PK model was used to develop a PK/PD model to study the effect of acyclovir levels on VZV viral load in plasma in immunocompromised patients. Results: Immunocompromised patients with known VZV viral loads in plasma were included for PK/PD modelling (N = 4, with 23 measure points); they were part of the population of 43 patients used for PK model building. The PK/PD model described the data well (r2 = 0.83). This is a hopeful first step in clarifying the pharmacodynamics of acyclovir; however, the data in this study are limited. Conclusions: Our preliminary PK/PD model can be used in further research to determine the effect of acyclovir levels on VZV viral load.

7 September 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GGGeeske F. Grit
Geeske F. Grit
MDMaaike van Dartel
Maaike van Dartel
LRLaura Rodwell
Laura Rodwell
HWHanneke van der Woude
Hanneke van der Woude
CBCornelis Boersma
Cornelis Boersma
DHDoranne Hilarius
Doranne Hilarius
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians. Registry‐based real‐world data (RWD) can enhance the evaluation and appropriate use of these novel medicines. Therefore, we developed a core dataset that provides a starting point to complement the evaluation of NSCLC drug effects based on registry‐based RWD. The core dataset was developed through a literature review of existing core datasets, followed by two multi‐stakeholder expert meetings for better understanding of important variables for drug evaluation purposes by different stakeholders. The experts included Dutch clinicians, hospital pharmacists, regulators, HTAb, industry representatives, academics, and a patient representative. Following the literature review, four existing core datasets were identified and used to extract important variables. After two expert meetings, this core dataset was redefined and the final core dataset includes general patient characteristics ( n = 6), disease‐specific factors ( n = 19), treatment details, including systemic therapy, surgery, and radiotherapy ( n = 22), outcomes such as death, progression, response ( n = 9), and patient‐reported outcome measures ( n = 17). This core dataset contains relevant variables that provides guidance for the collection of RWD to develop a relevant patient registry for NSCLC and to enhance its fitness‐for‐purpose. These RWD are intended to address most regulatory, HTA, and healthcare professionals' questions, thereby supporting the generation of real‐world evidence for the more appropriate use of NSCLC drugs.

1 March 2025 in Lung Cancer
Verified
Journal Article
Closed access
GGGeeske F. Grit
Geeske F. Grit
PMPeter G.M. Mol
Peter G.M. Mol
DHDoranne Hilarius
Doranne Hilarius